pulmonary disease

[키워드] accommodation acts Administered administration Adult patients Adverse adverse events alcohol Alcohol Abuse ALT anti-SARS-CoV-2 antibodies anti-SARS-CoV-2 antibody anticancer Antiviral antiviral therapy appearance approved AST blinded Blinding BMI body weight Bone marrow Breastfeeding CAD camostat Camostat mesylate Capsule Care Caregivers Cell Child chronic Chronic kidney disease chronic obstructive pulmonary disease chronic obstructive pulmonary disease (COPD) cirrhosis CKD clinical clinical condition Compliance Concomitant concurrent conducted control group Controlled trial convalescent plasma COPD Coronary artery Coronary artery disease cough COVID-19 COVID-19 pneumonia criteria cumulative defined diabetes Diabetes Mellitus diagnosed diagnosis of SARS-CoV-2 diarrhea disease Disease progression disease stage disorder dissemination double-blind Duration early disease Early phase of SARS-CoV-2 infection Efficacy element enrolled Enrollment enrolment EudraCT evaluate evening event evidence of Exanthema excluded exclusion criteria fatigue Fever fibrosis Germany GFR half-live headache high risk higher risk Hospitalization Hospitalized host cell hypersensitivity IgA deficiency immunization Inclusion inclusion criteria increased risk independent individual Infection infection with SARS-CoV-2 Influenza influenza A Informed consent inhibitor institution intervention arm intervention arms Kidney disease less Life expectancy likelihood Liver cirrhosis Local local Ethics Committee Mask mesylate moderate mother multicenter nasal nasal cannula Neutralizing number objective Obstructive obstructive pulmonary disease Older Ordinal Scale organ outcome outcomes oxygen oxygen demand Pancreatitis parallel group participant Participants passive immunization Patient patients hospitalized PCR Placebo plasma Plasma transfusion Pneumonia positive pregnant women Presence Prevent prevent disease progression primary endpoint progression protocol pulmonary disease pulmonary fibrosis Q-PCR randomization Randomized Randomized controlled trial receive recruitment reduce Regulatory reported risk factor safety monitoring committee Sample size SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 PCR screening visit Serine serine protease TMPRSS2 Serious Adverse Event Serious Adverse Events severe COVID-19 Shortness of breath SOC sore throat Stage Standard Standard of care stratified Stress Study protocol supplementary material Symptom symptom duration Symptoms tertiary care center tested the cell titers TMPRSS2 transfusion reaction Treatment treatment arm Trial Trial registration Tumor typical symptom typical symptoms ULN virus website WHO with COVID-19 women working hypothesis written Informed Consent
[DOI] 10.1186/s13063-021-05181-0 PMC 바로가기 [Article Type] Letter